Category Archives: Articles

The U.S. Food and Drug Administration approved Mobile ODT’s EVA (Enhanced Visual Assessment) System for marketing and sale in the United States. The tragedy of cervical cancer – strongly addressed in major urban areas – still plagues much of America, where it is increasingly difficult for a woman to get...

Compugen Ltd. (NASDAQ: CGEN) announced development of CGEN-15137, its cancer immunotherapy program for TIGIT. TIGIT is an immune checkpoint in the B7/CD28 family which has recently gained broad industry interest in the field of immuno-oncology. At the recent Annual Meeting of the Society for Immunotherapy of Cancer, the company disclosed...

Cancer treatment company BioSight, which recently received a $13 million investment from Mori Arkin and US investment fund Primera Capital, reports positive interim results of an initial efficacy trial for its Leukemia treatment product. The company’s product, Astarabine, had been tested on 15 Acute Myeloid Leukemia (AML) and Acute Lymphoblastic...

Israeli high-tech companies raised a total of $1.19 billion in the third quarter of 2016, the second highest quarterly amount in 10 years. The amount was significantly affected by the exceptional Ormat PIPE deal of $204 million, which captured 17 percent of total capital raised. Excluding the Ormat transaction, the...

On behalf of the MDDMI 2017 steering committee and the conference chairman, Prof. Rafi Beyar, Director of the Rambam Health Care Campus, we are pleased to invite you to take part at the Israel’s premier event for medical device development. The steering Committee encourages the submission of original Papers for...

VAXIL BIO LTD. (TSX VENTURE: VXL) has reported  preliminary pre-clinical results demonstrating anti-cancer activity of Immucin™ in combination with checkpoint inhibitors. Furthermore, Vaxil’s scientists have made significant progress for Orphan Designated product Immucin™ in demonstrating its ability to act as a neo-antigen, with potential to strongly stimulate the immune system. Vaxil has launched...

GOUR Medical, an animal health specialist , has listed on Marché Libre Euronext Paris (ISIN code: CH0342399851; Ticker: MLGML), the French securities market. GOUR Medical is a pharmaceutical company dedicated to the development and marketing of veterinary drugs for mature pets. Having first identified and acquired a number of drug...

Alma is preparing a therapy for testing in patients with Crohn’s Disease.The company plans to conduct the early stage clinical testing. Then, Alma will license the therapy to a larger company and collect royalties from drug sales. </p> Crowdfunding has emerged as a solution and a major opportunity to find...

BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of...

Avraham Pharmaceuticals Ltd.  has closed an investment round of approximately $4.0 million. Investors in the round include Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissum’s biotech holdings company, the Technion Research and Development Foundation Ltd. (TRDF)...

BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD), a rare progressive muscle-wasting disease characterized by swallowing difficulties (dysphagia), leading to the risk of aspiration of food into the lungs,...

Enzymotec announced that InCogTM, an innovative lipid composition that is intended to mimic certain characteristics of human breast milk contributing to cognitive development, demonstrated enhanced brain development and improved survival in a preclinical study. The study evaluated the effects of InCogTM in a term and preterm piglet model relevant for...

Can-Fite has submitted to the European Medicines Agency (EMA) a protocol design for its Phase III trial and Registration Plan for the Company’s lead compound CF101 in the treatment of rheumatoid arthritis following a pre-submission meeting with the EMA. The global trial is expected to commence in either the second...

Israeli big data and intensive care analytics startup Intensix has signed an agreement with Mayo Clinic in the US to commence a study of early predictions of life-threatening complications in a critical care setting. The study will focus on the feasibility of using the Intensix platform to predict patient deterioration...

An Israeli pharmaceutical firm could be the next big producer of erectile dysfunction treatments. Petah Tikvah-based Can-Fite announced Tuesday that the US Patent and Trademark Office (one of the last stages before the actual granting of a patent) issued a Notice of Allowance for the company’s “A3 Adenosine Receptor Allosteric...

Your preschooler wakes up with an earache and fever. You tell your boss you’ll be late to work, wangle a pediatrician appointment, bundle up the sick kid, sit in a waiting room full of other sick kids, spend five minutes with the doctor, and leave with a prescription and/or orders...

The Trendlines Group has entered into a definitive collaboration framework agreement with a major multinational medical corporation headquartered in Japan. This research partnership will see the firms mutually identify specific clinical opportunities. As part of the terms of the agreement, Trendlines Labs will develop innovative medical device products for manufacturing...

WIth more than 300 employees at four sites throughout Israel, Merck KgaA, a multifaceted chemical and technology company, has quietly emerged as one of the major multinational firms with a significant presence in Israel. The company announced this week that it was furthering its stake in Israeli tech by signing...

Six pediatric medical device innovations that address a significant yet unmet pediatric need were awarded a total of $250,000 in grant money at the third annual National Capital Consortium for Pediatric Device Innovation (NCC-PDI) Competition. ApiFix was awarded a $25,000 grant for its minimally invasive correction system for patients with a spinal...

Vaxil Bio has become the first Israeli biotech company to trade on the Toronto Stock Market. Vaxil’s shares are now trading under the symbol VXL. At a deemed value of $0.23 per share, the Company’s market value is approximately $11-Million. The Company’s financing and go-public were led by Sunel Securities Inc.</p> Vaxil...